粤万年青(301111) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥76,370,367.03, representing a 28.99% increase year-over-year[2] - The net profit attributable to shareholders was -¥1,003,417.13, a decrease of 117.64% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses was -¥3,632,482.37, reflecting a significant decline of 3,127.97% year-over-year[2] - The company's net profit for the first three quarters of 2024 decreased, mainly due to a reduction in gross profit from core business by ¥1,982,600, a decline in gross profit margin by 7.61%, and increased expenses related to new business expansions[13] - Net profit for Q3 2024 was CNY 14,027,447.67, a decrease of 53.7% from CNY 30,242,810.34 in the previous year[18] - The total comprehensive income attributable to the parent company for Q3 2024 was CNY 14,100,379.80, compared to CNY 30,491,841.57 in the same period last year, representing a decrease of approximately 53.8%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥856,990,549.21, showing a slight increase of 0.17% from the end of the previous year[2] - The company's total assets as of Q3 2024 were CNY 856,990,549.21, a marginal increase from CNY 855,535,468.09 at the end of the previous period[16] - Total liabilities increased to CNY 77,784,618.22 from CNY 77,330,290.56, showing a rise of 0.6%[16] - The equity attributable to shareholders of the parent company decreased to CNY 773,881,370.00 from CNY 776,174,544.06, reflecting a decline of 0.3%[16] Cash Flow - The company's cash flow from operating activities was -¥12,341,171.41, which is a 29.28% improvement compared to the same period last year[2] - Cash inflow from operating activities for Q3 2024 was CNY 229,823,388.87, an increase of 18.4% from CNY 194,238,091.95 in Q3 2023[20] - Cash outflow from operating activities totaled CNY 242,164,560.28, up from CNY 211,688,325.97 in the previous year, marking an increase of approximately 14.4%[20] - The net cash flow from operating activities for Q3 2024 was negative CNY 12,341,171.41, an improvement from negative CNY 17,450,234.02 in Q3 2023[20] - The net cash flow from investing activities was ¥14,700,270.87, a significant increase of 173.27% compared to the previous period, primarily due to reduced idle funds available for investment and higher cash inflows from investment activities[8] - Cash inflow from investment activities was CNY 161,551,091.36, down 31.1% from CNY 234,584,326.54 in the same period last year[21] - The net cash flow from investment activities improved to CNY 14,700,270.87, compared to negative CNY 20,062,049.27 in Q3 2023[21] Expenses - The company's management expenses increased by 61.52% to ¥28,418,583.06, primarily due to new healthcare business expansion costs[7] - The cost of goods sold rose by 37.96% to ¥92,137,632.62, attributed to increased sales in traditional Chinese medicine[7] - The company faced increased costs due to new business initiatives, including a ¥4,354,000 increase in expenses related to the healthcare sector[13] - Total operating costs for Q3 2024 were CNY 229,399,526.49, up from CNY 187,297,045.32, reflecting a year-over-year increase of 22.5%[17] - Research and development expenses for Q3 2024 amounted to CNY 6,416,666.62, slightly up from CNY 6,220,958.60, indicating a focus on innovation[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,302, with the largest shareholder, Guangdong Jino Health Technology Co., Ltd., holding 45.00% of shares[9] - The top ten shareholders collectively held 10.26% of the total share capital, with 合和投资控股 (Guangzhou) holding 11.25%[11] Other Notable Points - The company reported a significant increase in prepayments by 784.13% to ¥14,312,184.98, mainly due to increased procurement of Chinese medicinal materials[6] - The company experienced a 95.79% increase in contract liabilities, reaching ¥10,559,659.97, driven by changes in market demand and logistics[6] - The company reported an increase in accounts receivable to ¥76,918,264.20 from ¥66,295,494.78 in the previous period[14] - The total current assets increased to ¥531,000,821.31 from ¥509,656,274.43 at the beginning of the period[14] - The company's investment in debt investments decreased to ¥190,695,833.33 from ¥238,078,250.00[14] - Deferred income decreased to CNY 862,584.93 from CNY 1,275,506.91, a decline of 32.5%[16] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.0881, down from CNY 0.189 in the previous year, indicating a decline of about 53.4%[19] - The ending balance of cash and cash equivalents as of Q3 2024 was CNY 87,298,864.85, down from CNY 93,368,794.97 at the end of Q3 2023[21] - The company did not report any new product launches or significant market expansion strategies during the quarter[19]